Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.

Seferović PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS, Polovina MM, Komajda M, Seferović J, Sari I, Cosentino F, Ambrosio G, Metra M, Piepoli M, Chioncel O, Lund LH, Thum T, De Boer RA, Mullens W, Lopatin Y, Volterrani M, Hill L, Bauersachs J, Lyon A, Petrie MC, Anker S, Rosano GMC.

Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1673. [Epub ahead of print]

PMID:
31816162
2.

Genes lost during the transition from land to water in cetaceans highlight genomic changes associated with aquatic adaptations.

Huelsmann M, Hecker N, Springer MS, Gatesy J, Sharma V, Hiller M.

Sci Adv. 2019 Sep 25;5(9):eaaw6671. doi: 10.1126/sciadv.aaw6671. eCollection 2019 Sep.

3.

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.

Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J, Bayes-Genis A, Brutsaert D, Bugger H, Clarke K, Cosentino F, De Keulenaer G, Dei Cas A, González A, Huelsmann M, Iaccarino G, Lunde IG, Lyon AR, Pollesello P, Rena G, Riksen NP, Rosano G, Staels B, van Laake LW, Wanner C, Farmakis D, Filippatos G, Ruschitzka F, Seferovic P, de Boer RA, Heymans S.

Eur Heart J. 2018 Dec 21;39(48):4243-4254. doi: 10.1093/eurheartj/ehy596. No abstract available.

4.

Research update for articles published in EJCI in 2016.

Adlbrecht C, Blanco-Verea A, Bouzas-Mosquera MC, Brion M, Burtscher M, Carbone F, Chang TT, Charmandari E, Chen JW, Correia-Costa L, Dullaart RPF, Eleftheriades M, Fernandez-Fernandez B, Goliasch G, Gremmel T, Groeneveld ME, Henrique A, Huelsmann M, Jung C, Lichtenauer M, Montecucco F, Nicolaides NC, Niessner A, Palmeira C, Pirklbauer M, Sanchez-Niño MD, Sotiriadis A, Sousa T, Sulzgruber P, van Beek AP, Veronese N, Winter MP, Yeung KK, Bouzas-Mosquera A.

Eur J Clin Invest. 2018 Oct;48(10):e13016. doi: 10.1111/eci.13016. Epub 2018 Sep 16. Review. No abstract available.

PMID:
30099749
5.

Polyunsaturated fatty acids supplementation impairs anti-oxidant high-density lipoprotein function in heart failure.

Wurm R, Schrutka L, Hammer A, Moertl D, Berger R, Pavo N, Lang IM, Goliasch G, Huelsmann M, Distelmaier K.

Eur J Clin Invest. 2018 Sep;48(9):e12998. doi: 10.1111/eci.12998. Epub 2018 Aug 1.

6.

Quality of medical therapy in heart failure patients undergoing elective revascularisation: A protective effect of disease modifying therapy at discharge.

Wurm R, Huelsmann M, Hienert M, Seidl V, Wiedemann D, Laufer G, Kocher A, Adlbrecht C, Andreas M.

Sci Rep. 2017 Nov 2;7(1):14909. doi: 10.1038/s41598-017-15004-5.

7.

Disease management programs in chronic heart failure : Position statement of the Heart Failure Working Group and the Working Group of the Cardiological Assistance and Care Personnel of the Austrian Society of Cardiology.

Moertl D, Altenberger J, Bauer N, Berent R, Berger R, Boehmer A, Ebner C, Fritsch M, Geyrhofer F, Huelsmann M, Poelzl G, Stefenelli T.

Wien Klin Wochenschr. 2017 Dec;129(23-24):869-878. doi: 10.1007/s00508-017-1265-0. Epub 2017 Oct 27. No abstract available.

8.

Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure.

Poelzl G, Altenberger J, Pacher R, Ebner CH, Wieser M, Winter A, Fruhwald F, Dornaus C, Ehmsen U, Reiter S, Steinacher R, Huelsmann M, Eder V, Boehmer A, Pilgersdorfer L, Ablasser K, Keroe D, Groebner H, Auer J, Jakl G, Hallas A, Ess M, Ulmer H; Austrian Working Group on Heart Failure.

Int J Cardiol. 2014 Jul 15;175(1):83-9. doi: 10.1016/j.ijcard.2014.04.255. Epub 2014 May 2.

PMID:
24857326
9.

PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial.

Huelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, Adlbrecht C, Prager R, Luger A, Pacher R, Clodi M.

J Am Coll Cardiol. 2013 Oct 8;62(15):1365-72. doi: 10.1016/j.jacc.2013.05.069. Epub 2013 Jun 27.

10.

Portable recording for detecting sleep disorder breathing in patients under the care of a heart failure clinic.

Dolliner P, Brammen L, Graf S, Huelsmann M, Stiebellehner L, Gleiss A, Ubl P, Steurer G.

Clin Res Cardiol. 2013 Jul;102(7):535-42. doi: 10.1007/s00392-013-0563-4. Epub 2013 Apr 12.

PMID:
23579765
11.

Impact of tricuspid regurgitation on survival in patients with chronic heart failure: unexpected findings of a long-term observational study.

Neuhold S, Huelsmann M, Pernicka E, Graf A, Bonderman D, Adlbrecht C, Binder T, Maurer G, Pacher R, Mascherbauer J.

Eur Heart J. 2013 Mar;34(11):844-52. doi: 10.1093/eurheartj/ehs465. Epub 2013 Jan 18.

PMID:
23335604
12.

Repeat measurements of glycated haemoglobin A(1c) and N-terminal pro-B-type natriuretic peptide: divergent behaviour in diabetes mellitus.

Neuhold S, Resl M, Huelsmann M, Strunk G, Adlbrecht C, Rath C, Prager R, Luger A, Clodi M, Pacher R.

Eur J Clin Invest. 2011 Dec;41(12):1292-8. doi: 10.1111/j.1365-2362.2011.02539.x. Epub 2011 May 25.

PMID:
21615391
13.

Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care.

Adlbrecht C, Huelsmann M, Berger R, Moertl D, Strunk G, Oesterle A, Ahmadi R, Szucs T, Pacher R.

Eur J Clin Invest. 2011 Mar;41(3):315-22. doi: 10.1111/j.1365-2362.2010.02412.x. Epub 2010 Nov 10.

PMID:
21070222
14.

N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.

Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, Wagner B, Pacher R.

J Am Coll Cardiol. 2010 Feb 16;55(7):645-53. doi: 10.1016/j.jacc.2009.08.078.

15.

Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy.

Neuhold S, Huelsmann M, Strunk G, Struck J, Adlbrecht C, Gouya G, Elhenicky M, Pacher R.

Clin Chem. 2010 Jan;56(1):121-6. doi: 10.1373/clinchem.2009.125856. Epub 2009 Nov 2.

16.

Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.

Moertl D, Berger R, Struck J, Gleiss A, Hammer A, Morgenthaler NG, Bergmann A, Huelsmann M, Pacher R.

J Am Coll Cardiol. 2009 May 12;53(19):1783-90. doi: 10.1016/j.jacc.2009.01.057.

17.

B-type natriuretic peptide predicts benefit from a home-based nurse care in chronic heart failure.

Moertl D, Berger R, Hammer A, Huelsmann M, Hutuleac R, Pacher R.

J Card Fail. 2009 Apr;15(3):233-40. doi: 10.1016/j.cardfail.2008.11.002. Epub 2008 Dec 18.

PMID:
19327625
18.

NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus.

Huelsmann M, Neuhold S, Strunk G, Moertl D, Berger R, Prager R, Abrahamian H, Riedl M, Pacher R, Luger A, Clodi M.

Eur Heart J. 2008 Sep;29(18):2259-64. doi: 10.1093/eurheartj/ehn334. Epub 2008 Jul 23.

PMID:
18650200
19.

Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.

Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R.

J Am Coll Cardiol. 2008 Jul 22;52(4):266-72. doi: 10.1016/j.jacc.2008.03.050.

20.

Prognostic value of sequential measurements of amino-terminal prohormone of B-type natriuretic peptide in ambulatory heart failure patients.

Moertl D, Hammer A, Huelsmann M, Pacher R, Berger R.

Eur J Heart Fail. 2008 Apr;10(4):404-11. doi: 10.1016/j.ejheart.2008.02.018. Epub 2008 Mar 20.

21.

N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients.

Meyer B, Huelsmann M, Wexberg P, Delle Karth G, Berger R, Moertl D, Szekeres T, Pacher R, Heinz G.

Crit Care Med. 2007 Oct;35(10):2268-73.

PMID:
17717488
22.

Heart transplantation provides long-term survival benefit in stable patients experiencing heart failure without reverse left ventricular remodeling.

Meyer B, Moertl D, Huelsmann M, Kulemann V, Zuckermann A, Grimm M, Pacher R, Berger R.

Transplantation. 2006 Dec 15;82(11):1463-71.

PMID:
17164718
23.

Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure.

Berger R, Moertl D, Huelsmann M, Bojic A, Ahmadi R, Heissenberger I, Pacher R.

Eur J Heart Fail. 2007 Feb;9(2):202-8. Epub 2006 Jul 21.

24.

Comparison of soluble glycoprotein 130 and cardiac natriuretic peptides as long-term predictors of heart failure progression.

Gwechenberger M, Pacher R, Berger R, Zorn G, Moser P, Stanek B, Huelsmann M.

J Heart Lung Transplant. 2005 Dec;24(12):2190-5. Epub 2005 Nov 2.

PMID:
16364870
25.
26.

Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure.

Berger R, Huelsmann M, Strecker K, Moertl D, Moser P, Bojic A, Pacher R.

Eur J Clin Invest. 2005 Jan;35(1):24-31.

PMID:
15638816
27.

Natriuretic peptides and the prevalence of congestive heart failure in patients with pacemakers.

Gwechenberger M, Huelsmann M, Graf S, Berger R, Bonderman D, Stanek B, Rauscha F, Pacher R.

Eur J Clin Invest. 2004 Dec;34(12):811-7.

PMID:
15606723
28.

Oncostatin-M in myocardial ischemia/reperfusion injury may regulate tissue repair.

Gwechenberger M, Moertl D, Pacher R, Huelsmann M.

Croat Med J. 2004 Apr;45(2):149-57.

29.

Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines.

Delle Karth G, Buberl A, Geppert A, Neunteufl T, Huelsmann M, Kopp C, Nikfardjam M, Berger R, Heinz G.

Acta Anaesthesiol Scand. 2003 Nov;47(10):1251-6.

PMID:
14616323
30.

Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period.

Berger R, Strecker K, Huelsmann M, Moser P, Frey B, Bojic A, Stanek B, Pacher R.

J Heart Lung Transplant. 2003 Sep;22(9):1037-45.

PMID:
12957614
31.

Circadian variation in ventricular tachycardia and atrial fibrillation in a medical-cardiological ICU.

Delle Karth G, Reinelt P, Buberl A, Geppert A, Huelsmann M, Berger R, Heinz G.

Intensive Care Med. 2003 Jun;29(6):963-968. doi: 10.1007/s00134-003-1735-x. Epub 2003 Apr 16.

PMID:
12698245
32.

Prognostic impact of workload in patients with congestive heart failure.

Huelsmann M, Stefenelli T, Berger R, Frey B, Pacher R.

Am Heart J. 2002 Feb;143(2):308-12.

PMID:
11835036
33.

Neuromuscular electric stimulation in heart transplantation candidates with cardiac pacemakers.

Wiesinger GF, Crevenna R, Nuhr MJ, Huelsmann M, Fialka-Moser V, Quittan M.

Arch Phys Med Rehabil. 2001 Oct;82(10):1476-7.

PMID:
11588756
34.

B-type natriuretic peptides (BNP and PRO-BNP) predict longterm survival in patients with advanced heart failure treated with atenolol.

Berger R, Stanek B, Frey B, Sturm B, Huelsmann M, Bergler-Klein J, Pacher R.

J Heart Lung Transplant. 2001 Feb;20(2):251. No abstract available.

PMID:
11250499
35.

Elevation of serum big endothelin is associated with endothelial dysfunction in patients with chronic heart failure.

Berger R, Strecker K, Stanek B, Huelsmann M, Pacher R, Neunteufl T.

J Heart Lung Transplant. 2001 Feb;20(2):159. No abstract available.

PMID:
11250235
36.

Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failure.

Globits S, Frank H, Pacher B, Huelsmann M, Ogris E, Pacher R.

Am Heart J. 1998 Apr;135(4):592-7.

PMID:
9539472

Supplemental Content

Loading ...
Support Center